Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Epidemiology and Vaccinations in Infectious Diseases
share announcement

Epidemiology and Vaccinations in Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Epidemiology and Vaccination".

Deadline for manuscript submissions: 30 September 2026 | Viewed by 2092

Special Issue Editors

Dr. Alessio Facciolà

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy
Interests: epidemiology of infectious diseases; vaccinations; public health; environmental health; climate change and infectious diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Antonio Laganà

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98125 Messina, Italy
Interests: epidemiology of infectious diseases; vaccinations; public health; environmental health; climate change and infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We invite you to contribute to our Special Issue titled “Epidemiology and Vaccinations in Infectious Diseases.” This issue aims to gather original research articles and reviews that focus on the vital topic of infectious disease epidemiology and prevention.

Infectious diseases remain a leading cause of morbidity and mortality worldwide. Continuous monitoring of their epidemiology is essential for global public health, as it enables the detection of changes in expected case distributions and helps address emerging critical issues. Vaccinations play a vital role in preventing these diseases. While traditional vaccines have been effective for many years, it is increasingly important to develop new vaccines to manage both emerging and re-emerging diseases. In this Special Issue, we will address current issues and future perspectives. Topics of interest include outbreaks of classic and emerging infections, changes in the typical epidemiology of diseases, the spread of antimicrobial resistance, the development of new vaccines, and the implementation of vaccination campaigns.

We look forward to receiving your contributions. 

Dr. Alessio Facciolà
Dr. Antonio Laganà
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epidemiology of infectious diseases
  • traditional and innovative vaccinations
  • epidemic and pandemic risk
  • global public health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 2973 KB  
Article
Mpox Vaccination Willingness, Concern Profiles, and Associated Factors Among Men Who Have Sex with Men in Changsha, China
by Yingying Zhou, Wenqiang Wang, Yun Kuang, Qiang Hu, Lin Shen, Qiangming Xie and Zhi Xie
Vaccines 2026, 14(5), 428; https://doi.org/10.3390/vaccines14050428 - 10 May 2026
Viewed by 463
Abstract
Background: Mpox vaccination is an important prevention strategy for men who have sex with men (MSM), yet responses to vaccination may not be adequately captured by a simple willing-versus-unwilling framing. We examined correlates of vaccination willingness and heterogeneity within the delayed/refused responses [...] Read more.
Background: Mpox vaccination is an important prevention strategy for men who have sex with men (MSM), yet responses to vaccination may not be adequately captured by a simple willing-versus-unwilling framing. We examined correlates of vaccination willingness and heterogeneity within the delayed/refused responses subgroup in Changsha, China. Methods: A cross-sectional survey was conducted using respondent-driven sampling (RDS). Vaccination willingness was classified as immediate willingness versus delayed/refused responses. Analyses included cluster-robust logistic regression, RDS-weighted regression, generalized estimating equations, and a recruiter-linked network-lag model. Among respondents with delayed/refused responses, concern profiles were explored using unsupervised clustering of standardized concern items. Results: Among 405 recruited MSM without a self-reported mpox infection history, immediate willingness and delayed/refused responses were nearly equally distributed, indicating that lack of immediate willingness was common. Across primary models, ever use of pre-exposure prophylaxis (PrEP) and higher mpox-related information exposure frequency were the most consistent correlates of immediate willingness versus delayed/refused responses, whereas basic sociodemographic variables showed little evidence of independent association. Within the delayed/refused group, three partially overlapping patterns emerged: broadly elevated cross-domain concern, low-concern delay with few strongly endorsed barriers, and more selective safety- and burden-related concerns. These findings suggest that a lack of immediate willingness may arise through different psychosocial pathways rather than a single common mechanism. Conclusions: Mpox vaccination willingness among MSM in Changsha appeared to be shaped more by prevention-related behaviors and psychosocial factors than by basic sociodemographic profiles alone. Vaccination strategies may benefit from cross-topic sexual-health communication, integrated prevention efforts, and subgroup-sensitive approaches to delayed or refused willingness. Full article
(This article belongs to the Special Issue Epidemiology and Vaccinations in Infectious Diseases)
►▼ Show Figures

Figure 1

13 pages, 605 KB  
Article
Pneumococcal Meningitis in a Region of Northern Spain, 1993–2023: Incidence Trends, Clinical Features, Recurrences, and Antibiotic Resistance
by Ayla Manzanal, Diego Vicente, Iñigo Ansa, Maitane Arrastia, Pedro Vallejo and José María Marimón
Vaccines 2026, 14(2), 131; https://doi.org/10.3390/vaccines14020131 - 28 Jan 2026
Viewed by 1209
Abstract
Background: Streptococcus pneumoniae is currently the leading cause of acute bacterial meningitis. This study assessed the impact of pneumococcal conjugate vaccines (PCVs) on pneumococcal meningitis in Gipuzkoa, north of Spain, between 1993 and 2023. Methods: All cases were serotyped and tested for [...] Read more.
Background: Streptococcus pneumoniae is currently the leading cause of acute bacterial meningitis. This study assessed the impact of pneumococcal conjugate vaccines (PCVs) on pneumococcal meningitis in Gipuzkoa, north of Spain, between 1993 and 2023. Methods: All cases were serotyped and tested for antimicrobial susceptibility, with medical records reviewed since 2013. Overall, 193 patients were diagnosed (178 patients), averaging 6.2 cases annually. Results: Pneumococcal meningitis annual incidence decreased significantly after PCVs introduction, from 1.99 cases per 100,000 inhabitants in 1993–2001 (before PCV7) to 1.64 in 2002–2010 (PCV7 period) and further to 1.13 in 2011–2023 (PCV13 period). This decline was observed in all age groups except for adults aged ≥65 years, in whom the reduction was observed only after PCV13 introduction. The greatest reduction was observed in children under five. The incidence of meningitis caused by vaccine serotypes decreased following the progressive introduction of PCVs, but non-PCV serotypes increased from 0.70 to 0.95 cases per 100,000 between 1993–2001 and 2011–2023. Otitis media was the most common source of infection, followed by CSF fistula. Most cases (85%) required ICU admission; 67.5% showed sequels at discharge, mainly sensorineural hearing loss, and the 30-day mortality rate was 11.1%. Recurrent pneumococcal meningitis represented 7.8% of cases, associated with head trauma, with favorable outcomes and no mortality. Between 1993–2001 and 2002–2010, penicillin and cefotaxime resistance decreased from 25.4% to 13.3% (47.6% reduction) and from 19.7% to 5% (74.6% reduction), respectively. In 2011–2023, cefotaxime resistance stabilized, but penicillin resistance rose to 32.3%, mainly due to non-PCV13 serotypes. Conclusions: The use of PCV reduced the incidence of pneumococcal meningitis in the region, but penicillin resistance has increased in recent years, due to the rise in non-PCV13 serotypes. Full article
(This article belongs to the Special Issue Epidemiology and Vaccinations in Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop